Print page |
Email page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
To the Holders of the 0% Convertible Senior Unsecured Notes Due 2026 (the "Notes") issued by Monogram Biosciences, Inc. (the "Company"):
Reference is made to that certain Indenture (the "Indenture"), dated as of January 12, 2007, between the Company and U.S. Bank National Association (the "Trustee"). All capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Indenture.
The Company hereby notifies you that no Additional Shares will be issued in connection with the Change of Control, resulting from the acquisition of the Company by Laboratory Corporation of America Holdings. Pursuant to Section 15.13 of the Indenture, the Company is required, after determination of the actual number of Additional Shares to be issued in respect of a Change of Control, to publish a notice containing the actual number of Additional Shares in a newspaper published in the English language, customarily published each Business Day and of general circulation in the City of New York or publish such information on the Company's website or through such other public medium as the Company may use at the time.
GENERAL INFORMATION,
This notice is being sent pursuant to Section 15.13 of the Indenture. The summary of the terms of the Indenture set forth above is qualified in its entirety to the text of the Indenture. The Company makes no representation as to the accuracy or the correctness of the CUSIP number contained in this notice; reliance may be placed only on the identification numbers printed on the Notes, and this notice shall not be affected by any defect in such CUSIP number. Questions and requests for assistance in connection with conversion or redemption of the Notes may be directed to Kathy Hibbs, SVP, General Counsel, of the Company, Telephone: (650) 624-4243.
MONOGRAM BIOSCIENCES, INC.,